

Emily Chu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299078/publications.pdf>

Version: 2024-02-01

80
papers

1,364
citations

430874

18
h-index

377865

34
g-index

80
all docs

80
docs citations

80
times ranked

2205
citing authors

#	ARTICLE	IF	CITATIONS
1	Acral lentiginous melanoma in the era of immune checkpoint blockade and targeted therapy: A National Cancer Database analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 169-172.	1.2	3
2	Optimizing Detection of Lymphatic Invasion in Primary Cutaneous Melanoma With the Use of D2-40 and a Paired Melanocytic Marker. <i>American Journal of Dermatopathology</i> , 2022, 44, 21-27.	0.6	4
3	Local recurrence in patients undergoing wide excision and sentinel lymph node biopsy for cutaneous malignant melanoma: A single-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 247-250.	1.2	1
4	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	1.3	5
5	ASO Visual Abstract: Prognostic Significance of Primary-Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
6	Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 5207-5216.	1.5	10
7	Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
8	SnapshotDx Quiz: March 2022. <i>Journal of Investigative Dermatology</i> , 2022, 142, e27-e32.	0.7	0
9	Slow-Growing Nodule in a Patient With Li-Fraumeni Syndrome: Challenge. <i>American Journal of Dermatopathology</i> , 2022, 44, e37-e38.	0.6	0
10	Slow-Growing Nodule in a Patient With Li-Fraumeni Syndrome: Answer. <i>American Journal of Dermatopathology</i> , 2022, 44, 312-313.	0.6	0
11	Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma: A national cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 754-760.	1.2	7
12	Association between halo nevi and melanoma in adults: A multicenter retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1164-1166.	1.2	6
13	Lymphedematous verrucous changes of the genital skin: an extraintestinal manifestation of Crohn disease. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 465-468.	1.3	1
14	SnapshotDx Quiz: March 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e27-e32.	0.7	0
15	Distinct Signatures of Genomic Copy Number Variants Define Subgroups of Merkel Cell Carcinoma Tumors. <i>Cancers</i> , 2021, 13, 1134.	3.7	6
16	The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution experience. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1096-1098.	1.2	30
17	Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-EPD1/anti-CTLA4 therapy. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1111-1112.	1.3	7
18	The accuracy of detecting melanoma on frozen section melanoma antigen recognized by T cells 1 (MART-1) stains and on permanent sections of previously frozen tissue: A prospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1764-1766.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade. <i>Surgical Pathology Clinics</i> , 2021, 14, 209-224.	1.7	3
20	Association of the Affordable Care Act's Medicaid expansion with the diagnosis and treatment of clinically localized melanoma: A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1628-1635.	1.2	9
21	SnapshotDx Quiz: July 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e77-e82.	0.7	0
22	Shedding Light on Disparities in Melanoma Care. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1625-1626.	0.7	0
23	Response to a letter to the editor regarding "limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population-level"; <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e197-e198.	1.2	0
24	A Blue-Gray Macule on the Back: Challenge. <i>American Journal of Dermatopathology</i> , 2020, 42, e4-e4.	0.6	0
25	A Blue-Gray Macule on the Back: Answer. <i>American Journal of Dermatopathology</i> , 2020, 42, 65-65.	0.6	2
26	Use of new molecular tests for melanoma by pigmented-lesion experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 245-247.	1.2	8
27	SnapshotDx Quiz: November 2020. <i>Journal of Investigative Dermatology</i> , 2020, 140, e121-e126.	0.7	0
28	Urethral involvement is associated with higher mortality and local recurrence in vulvar melanoma: a single institutional experience. <i>Human Pathology</i> , 2020, 104, 1-8.	2.0	0
29	Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy. <i>Immunotherapy</i> , 2020, 12, 951-956.	2.0	7
30	Evaluation of the Merits and Limitations of Evidence-Based Medicine. <i>JAMA Dermatology</i> , 2020, 156, 924.	4.1	0
31	Comparison of C3d immunohistochemical staining to enzyme-linked immunosorbent assay and immunofluorescence for diagnosis of bullous pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 172-178.	1.2	11
32	An Inpatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome. <i>JAMA Dermatology</i> , 2020, 156, 676.	4.1	8
33	Gene Expression Profile Testing for Thin Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 837.	4.1	9
34	Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 860-869.	1.2	5
35	Generalized congenital epithelioid blue nevi (pigmented epithelioid melanocytomas) in an infant: Report of case and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 954-959.	1.3	3
36	Expression of p15 in a spectrum of spitzoid melanocytic neoplasms. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 310-316.	1.3	5

#	ARTICLE	IF	CITATIONS
37	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 190-194.	1.3	6
38	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	4.1	29
39	Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 574.	4.1	19
40	Impact of a smartphone application on skin self-examination rates in patients who are new to total body photography: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 564-567.	1.2	14
41	Cutaneous Metastases of Melanoma Mimicking Interstitial Granulomatous Processes. <i>American Journal of Dermatopathology</i> , 2018, 40, 706-707.	0.6	2
42	The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 245-251.	1.2	26
43	SnapshotDx Quiz: March 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e31.	0.7	0
44	Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 74-77.	1.3	34
45	Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. <i>JAMA Dermatology</i> , 2018, 154, 1401.	4.1	30
46	Pembrolizumab-induced sarcoidal infusion site reaction. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 727-729.	1.3	9
47	MART-1-labeled melanocyte density and distribution in actinic keratosis and squamous cell cancer in situ: Pagetoid melanocytes are a potential source of misdiagnosis as melanoma in situ. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 734-742.	1.3	4
48	SnapshotDx Quiz: July 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e47.	0.7	0
49	Piloting the Use of Smartphones, Reminders, and Accountability Partners to Promote Skin Self-Examinations in Patients with Total Body Photography: A Randomized Controlled Trial. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 779-785.	6.7	13
50	Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. <i>JAMA Dermatology</i> , 2018, 154, 1057.	4.1	86
51	Clinical factors associated with subclinical spread of in situ melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 707-713.	1.2	36
52	Clinical and pathologic factors associated with subclinical spread of invasive melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 714-721.	1.2	30
53	Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate. <i>JAMA Dermatology</i> , 2017, 153, 719.	4.1	6
54	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation. <i>Nature Communications</i> , 2017, 8, 15397.	12.8	104

#	ARTICLE	IF	CITATIONS
55	Reply to: "Statistical and methodological issues". Journal of the American Academy of Dermatology, 2017, 77, e115-e116.	1.2	0
56	Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. JAMA Dermatology, 2017, 153, 866.	4.1	50
57	Development of <i>RET</i> mutant cutaneous angiosarcoma during <i>BRAF</i> inhibitor therapy. Journal of Cutaneous Pathology, 2017, 44, 1053-1056.	1.3	4
58	Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma. JAMA Dermatology, 2016, 152, 836.	4.1	14
59	Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group. Journal of the American Academy of Dermatology, 2016, 75, 356-363.	1.2	30
60	Differential T cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals. Experimental Dermatology, 2016, 25, 245-247.	2.9	6
61	p15 Expression Differentiates Nevus from Melanoma. American Journal of Pathology, 2016, 186, 3094-3099.	3.8	14
62	Assessment of smartphone applications for total body digital photography-guided skin exams by patients. Journal of the American Academy of Dermatology, 2016, 75, 1063-1064.e1.	1.2	10
63	<i>CDKN2A</i> mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. British Journal of Dermatology, 2016, 175, 785-789.	1.5	27
64	Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. Journal of Cutaneous Pathology, 2016, 43, 787-791.	1.3	63
65	Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatology, 2016, 152, 227.	4.1	8
66	Photo-distributed lichenoid eruption secondary to direct antiviral therapy for hepatitis C. Journal of Cutaneous Pathology, 2015, 42, 769-773.	1.3	17
67	The histopathologic features of Integra® Dermal Regeneration Template. Journal of Cutaneous Pathology, 2015, 42, 368-369.	1.3	12
68	Presentation of Acute Megakaryoblastic Leukemia Associated with a <i>GATA1</i> Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder. Pediatric Dermatology, 2015, 32, e204-7.	0.9	1
69	Patients' Preferences for Biopsy Result Notification in an Era of Electronic Messaging Methods. JAMA Dermatology, 2015, 151, 513.	4.1	47
70	Mucinous Nevus. JAMA Dermatology, 2014, 150, 1018.	4.1	18
71	Vemurafenib-induced interface dermatitis manifesting as radiation recall and a keratosis pilaris-like eruption. Journal of Cutaneous Pathology, 2014, 41, 539-543.	1.3	13
72	Alcohol-induced vasculitis: Case report and commentary. Journal of the American Academy of Dermatology, 2014, 70, e42-e43.	1.2	5

#	ARTICLE	IF	CITATIONS
73	Lymphedematous verrucous changes simulating squamous cell carcinoma in long-standing hidradenitis suppurativa. <i>International Journal of Dermatology</i> , 2013, 52, 808-812.	1.0	14
74	The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma. <i>Current Dermatology Reports</i> , 2013, 2, 84-100.	2.1	6
75	Coxsackievirus A6-Induced Hand-Foot-Mouth Disease. <i>JAMA Dermatology</i> , 2013, 149, 1419.	4.1	49
76	Reliability and Convergent Validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for Assessing Cutaneous Sarcoidosis. <i>JAMA Dermatology</i> , 2013, 149, 550.	4.1	40
77	<i>NRAS</i> and <i>BRAF</i> mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib. <i>Journal of Clinical Oncology</i> , 2013, 31, 9017-9017.	1.6	0
78	Shiitake dermatitis: a report of 3 cases and review of the literature. <i>Cutis</i> , 2013, 91, 287-90.	0.3	17
79	Cutaneous Manifestations of <i>DOCK8</i> Deficiency Syndrome. <i>Archives of Dermatology</i> , 2012, 148, 79.	1.4	129
80	Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1265-1272.	1.2	166